One explanation for this discrepancy could be the fact that the systemic administration of IL-33 induces Th2 responses, which might result in a different outcome in the setting of atherosclerosis as compared to physiological amounts of endogenous IL-33 [35,103]. Here, IL33 is linked to atherosclerosis.